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Background: Elderly individuals who have memory problems without significant limitations in activities of daily
living are often diagnosed as having mild cognitive impairment (MCI). Some of these individuals progress to
dementia. Several cognitive enhancers (for example donepezil, galantamine, rivastigmine, memantine) have been
approved for use in people with Alzheimer’s dementia but their use in patients with MCI is unclear. We aimed to
determine the comparative effectiveness, safety, and cost of cognitive enhancers for MCI through a systematic
review and network (that is, indirect comparisons) meta-analysis.
Design/Methods: We will include studies that examine the use of cognitive enhancers compared to placebo,
supportive care, or other cognitive enhancers among patients diagnosed with MCI. Outcomes of interest include
cognition and function (primary outcomes), as well as behavior, quality of life, safety, and cost (secondary
outcomes). We will include all experimental studies (randomized controlled trials, quasi-randomized controlled trials,
controlled clinical trials), quasi-experimental studies (controlled before-after, interrupted time series), and
observational studies (cohort, case–control). Studies will be included regardless of publication status (that is, we will
include unpublished studies), year, or language of dissemination.
To identify potentially relevant material, we will search the following electronic databases from inception onwards:
MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, and Ageline. The electronic database
search will be supplemented by scanning the reference lists of included studies, searching Google and organization
websites for unpublished or difficult to locate material literature, and contacting experts.
Two reviewers will independently screen the studies for inclusion using the eligibility criteria established a priori and
independently extract data. Risk of bias will be assessed using the Cochrane Risk of Bias tool for experimental and
quasi-experimental studies and the Newcastle Ottawa Scale for observational epidemiology studies. Meta-analysis
and network meta-analysis are planned, if the studies are deemed statistically, methodologically, and clinically
homogenous.
Discussion: Our systematic review will provide important information regarding the benefits, costs, and harms of
cognitive enhancers for patients with MCI. This information can be used to assist healthcare providers,
policy-makers, MCI patients and their family regarding the use of these agents.
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Mild cognitive impairment (MCI) is a diagnosis
reserved for elderly individuals who have memory pro-
blems without significant activities of daily living lim-
itations [1]. The diagnostic criteria for MCI include:
subjective complaint of memory loss; memory impair-
ment on brief cognitive or neuropsychological testing;
decline from previously normal level of function;
present basic daily functioning unchanged; no medical,
neurologic or psychiatric explanation for memory loss;
and, cognitive impairment not meeting the criteria for
dementia [1]. MCI has recently been recognized as a
distinct condition.
A recent systematic review estimated the prevalence
and incidence of MCI reported in population-based
studies [2]. Ten studies conducted in China, France,
Italy, Korea, and the United States reported that the
prevalence of MCI ranged from 3% to 42%. The preva-
lence of MCI increased with age. For individuals 65 years
of age or older, the incidence of MCI ranged from 21.5
to 71.3 per 1,000 person-years based on data from two
studies conducted in the United States and one study
conducted in Italy [2]. These estimates suggest that a
large proportion of the population is affected by MCI.
Patients with MCI may progress to dementia, thus there
is interest in initiating treatment that may prevent or
slow this progression.
Pharmacological treatment for Alzheimer’s dementia
(AD) includes cholinesterase inhibitors (for example
donepezil, galantamine, rivastigmine), as well as an N-
Methyl-D-aspartic acid (NMDA) receptor antagonist,
memantine (Ebixa, Lundbeck) [3]. Acetylcholinesterase
inhibitors donepezil (Aricept, Eisai/Pfizer), rivastigmine
(Exelon, Novartis), and galantamine (Reminyl, Shire) act
by increasing the concentration of acetylcholine at the
neurotransmitter sites [4]. Galantamine also modulates
activity at nicotinic receptors [4]. Memantine works on
the glutamatergic system and modulates the neurotrans-
mitter glutamate [4]. Although cognitive enhancers have
not been widely approved for patients with MCI and are
available by special authorization in some countries (for
example, Canada), patients and their family members
are requesting these agents, making this a challenge in
the primary and specialty care settings [1].
Given their increasing use, our objectives are to exam-
ine the comparative effectiveness, safety, and cost of
cognitive enhancers for MCI through a systematic re-
view and network meta-analysis (that is, indirect com-
parison meta-analysis). Specifically, our research
questions are:
1. What is the efficacy of cognitive enhancers
(donepezil, rivastigmine, galantamine, memantine)
vs. placebo or best supportive care for MCI?2. What is the comparative effectiveness of cognitive
enhancers with similar modes of action (donezepil
and rivastigmine) vs. galantamine and memantine
for MCI?
3. What is the comparative safety of cognitive
enhancers for MCI?
4. What is the comparative cost associated with
cognitive enhancers for MCI?
Methods/Design
This systematic review protocol was developed using
guidance from the PRISMA Statement [5]. It was peer-
reviewed by experts in pharmacology, statistics, and
systematic reviews. Our protocol is registered in the
PROSPERO database (CRD42012002234) and is closely-
related to another systematic review protocol that fo-
cuses on cognitive enhancers for AD (CRD42012001948)
(Tricco, unpublished paper submitted to BMC SRs).
Eligibility criteria
Studies examining patients diagnosed with MCI using
established criteria (for example, Montréal Cognitive As-
sessment [6] and DemTect [7] will be included. Studies
must examine cognitive enhancers approved for use for
AD in Canada (donepezil, rivastigmine, galantamine,
memantine) compared with other cognitive enhancers,
memantine or placebo and/or supportive care. These
agents are also approved for AD in many other coun-
tries, including Australia, United States, and the United
Kingdom. Supportive care will include social support,
functional assistance, caregiver support, information,
education, community service, and other non-
pharmacological strategies.
We will include experimental studies (for example,
randomized controlled trials [RCTs], quasi-randomized
trials, controlled clinical trials), quasi-experimental stud-
ies (such as interrupted time series, controlled before
and after studies), and observational epidemiology stud-
ies (for example, cohort, case–control studies). Inclusion
will not be limited by publication status (that is, we will
include unpublished material), year, or language of dis-
semination. Potentially relevant articles not written in
English will be translated.
Information sources and literature search
The main literature search will be conducted in the fol-
lowing electronic databases: MEDLINE (OVID interface,
1948 onwards), EMBASE (OVID interface, 1947 on-
wards), the Cochrane Methodology Register (current
issue), Cochrane Central Register of Controlled Trials
(CENTRAL, current issue), CINAHL (EBSCO interface,
1980 onwards), and Ageline (EBSCO interface, 1961 on-
wards). The search strategies will be developed using
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to cognitive enhancers for MCI patients.
The electronic database search will be supplemented
by searching for difficult to locate or unpublished mater-
ial (that is, grey literature) using methods (Tricco, un-
published paper submitted to BMC SRs). Briefly, we will
search public health and trial registry websites, websites
of organizations that produce guidelines, conference
proceeding abstracts, Google, key journals, and contact
manufacturers to obtain their Scientific Information
Packets for the medications. Literature saturation will be
ensured by searching the authors’ personal files, scan-
ning the reference lists of included studies and relevant
reviews, and contacting researchers and healthcare pro-
viders who are active in this field.
The literature searches will be conducted by an experi-
enced librarian (Perrier) and peer-reviewed by another
librarian using Peer Review of Electronic Search Strat-
egies (PRESS) [8]. The draft literature search can be
found in the Appendix. For simplicity, the literature
search was conducted in conjunction with another sys-
tematic review on a closely-related topic (Tricco, unpub-
lished paper submitted to BMC SRs). The two reviews
will be separated after full-text screening. The results
from the literature search will be uploaded to our online
SysRev Tool, which will be used for screening the results
from the literature search [9].
Study selection process
We will calibrate the inclusion and exclusion criteria
by pilot-testing a random sample of 50 citations result-
ing from the search. A kappa statistic and the percent
agreement will be used to calculate inter-rater agree-
ment for study inclusion between reviewers [10]. If
poor to moderate agreement is observed (that is, per-
cent agreement less than 70% or a kappa statistic less
than 0.6), the inclusion and exclusion criteria will be
revised. All citations and full-text articles will be
reviewed by two reviewers independently. Conflicts will
be resolved by discussion or the involvement of a third
reviewer.
Data items and data collection process
Key stakeholders (for example, patients, healthcare pro-
viders, policy-makers) will be engaged to refine the key
outcomes. Potential outcomes of interest include:
– Cognition: Mini-mental state examination, Goal
Attainment Scale, Severe Impairment Battery
– Function: Bristol Activities of Daily Living Scale,
Caregiver-rated Modified Crichton Scale, Disability
Assessment for Dementia, the Interview for
Deterioration in Daily living activities in Dementia,
Nurses Observation Scale for Geriatric PatientsActivities of Daily Living subscale, the Progressive
Deterioration Scale
– Behavior: Neuropsychiatric Inventory
– Global Status: Clinician Interview-Based Impression
of Change Incorporating Caregiver Information
scale, Clinical Global Impression of Change
– Clinical Outcomes: Mortality, Health-Related
Quality of Life, Institutionalization, Falls, Balance;
Harms (number of adverse events (for example,
nausea, vomiting, diarrhea, dizziness, weight loss,
hospitalizations, bradycardia), number of
withdrawals, number of withdrawals due to adverse
events, severity and timing of adverse events);
Benefits to caregivers (for example, caregiver stress)
– Costs and cost-effectiveness
The data will be abstracted and categorized as study
characteristics (for example, study design, year of con-
duct, setting), patient characteristics (such as type and
number of patients, mean age, MCI diagnosis criteria,
MCI severity, baseline cognition, co-morbidities), pri-
mary outcome results (for example, cognition, function),
and secondary outcome results (such as behavior, quality
of life, costs, falls, balance, and harms).
We will calibrate the online data extraction form by
pilot-testing a random sample of five included studies.
Two reviewers will abstract all data independently and
conflicts will be resolved by discussion or the involve-
ment of a third reviewer.
We will abstract data based on clinically and methodo-
logically relevant follow-up time periods. These include after
3, 6, 12, and 24 months of follow-up. We will also identify
multiple publications reporting data from the same group
(that is, companion reports) to ensure that data is not
counted twice in meta-analysis. Study authors will be con-
tacted for further information when the data are unclear.
Methodological quality/risk of bias appraisal
We will use the Cochrane Risk of Bias Tool to appraise
RCTs [11] and the Cochrane Effective Practice and
Organization of Care Risk of Bias Tool for controlled clin-
ical trials, interrupted time series, and controlled before-
after studies [12]. The Newcastle-Ottawa Scale will be
used for cohort studies and case–control studies [13].
Summary of findings tables will be compiled to show the
relevance and level of evidence across all of the included
studies using Grading of Recommendations Assessment
Development and Evaluation (GRADE) [14]. The
McHarm tool [15] will be used to specifically examine ad-
verse drug reactions reported in the included studies.
Synthesis
We will first describe our results narratively. We will
subsequently conduct meta-analysis using a random-
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ately. Clinical, methodological, and statistical heterogen-
eity will be examined and meta-regression analysis will
be conducted if significant statistical heterogeneity is
identified (that is, I2 statistic> 60%) [17]. Missing data
will be imputed using established methods [18] and we
will examine the effect of the missing data on our results
using an established method [19].
If the data allow, network (such as, indirect compari-
son) meta-analysis will be conducted to rank treatment
efficacy among all the available treatments using the
WinBUGS software (MRC Biostatistics Unit, Cambridge,
England) [20]. Sensitivity analyses will be conducted to
assess the effect of inclusion of trials with high rates of
dropouts, missing data imputations, instruments used
for the primary outcomes, average adherence between
groups, inclusion of observational studies in the network
meta-analysis, and use of different priors for variance
parameters in the network meta-analysis [21].
Discussion
According to a recent systematic review, the prevalence
of MCI increases with age, with population-based stud-
ies reporting prevalence estimates as high as 42% [2].
The incidence of MCI among seniors ranged from 21.5
to 71.3 per 1,000 person-years [2]. These estimates sug-
gest that our systematic review results have the potential
to influence a large proportion of the population. Our
results will enable healthcare providers, policy-makers,
MCI patients and their family members make decisions
regarding the use of these agents.
As highlighted previously (Tricco, unpublished
paper submitted to BMC SRs), we will employ a
multifaceted knowledge translation strategy to ensure
our results reach potential endusers. For example, we
will publish our results in an open access journal
present our findings at relevant meetings (such as the
American Geriatrics Society). We will also dissemin-
ate our results through newsletters of interested orga-
nizations (for example, Alzheimer’s Society), create an
educational module for healthcare providers and use
our results to inform the development of a patient
decision aid.
Appendix: literature search
Database: Ovid MEDLINE(R) <1948 to November
Week 2 2011>, Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations<November 22, 2011>
Search Strategy:
1. alzheimer$.mp.
2. “benign senescent forgetfulness”.mp.
3. binswanger$.mp.
4. (chronic adj2 cerebrovascular).mp.5. (cognit$ adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
6. (cerebr$ adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
7. (memory adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
8. (mental adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
9. (ne?rocognit$ adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
10.(ne?ro-cognit$ adj2 (impair$ or declin$ or deficit$ or
degenerat$ or deteriorat$ or los$ or disorder$ or
complain$ or disturb$)).mp.
11.((cognit$ or memory or cerebral or brain) adj2
(improv$ or enhanc$ or perform$ or process$ or





















32.(“AA CD” or AACD).tw.
33.(“AA MI” or AAMI).tw.
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